Cargando…
P1067: ESTIMATING THE RELATIVE EFFICACY OF FAVEZELIMAB WHEN USED IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH PD-1–REFRACTORY CLASSICAL HODGKIN LYMPHOMA
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431435/ http://dx.doi.org/10.1097/01.HS9.0000971164.88567.72 |
| _version_ | 1785091201824718848 |
|---|---|
| author | Armand, Philippe Luigi Zinzani, Pier Timmerman, John Johnson, Nathalie Lavie, David Thiagarajan, Kannan Topp, Brian Pillai, Pallavi Herrera, Alex F. |
| author_facet | Armand, Philippe Luigi Zinzani, Pier Timmerman, John Johnson, Nathalie Lavie, David Thiagarajan, Kannan Topp, Brian Pillai, Pallavi Herrera, Alex F. |
| author_sort | Armand, Philippe |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10431435 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104314352023-08-17 P1067: ESTIMATING THE RELATIVE EFFICACY OF FAVEZELIMAB WHEN USED IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH PD-1–REFRACTORY CLASSICAL HODGKIN LYMPHOMA Armand, Philippe Luigi Zinzani, Pier Timmerman, John Johnson, Nathalie Lavie, David Thiagarajan, Kannan Topp, Brian Pillai, Pallavi Herrera, Alex F. Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10431435/ http://dx.doi.org/10.1097/01.HS9.0000971164.88567.72 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Armand, Philippe Luigi Zinzani, Pier Timmerman, John Johnson, Nathalie Lavie, David Thiagarajan, Kannan Topp, Brian Pillai, Pallavi Herrera, Alex F. P1067: ESTIMATING THE RELATIVE EFFICACY OF FAVEZELIMAB WHEN USED IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH PD-1–REFRACTORY CLASSICAL HODGKIN LYMPHOMA |
| title | P1067: ESTIMATING THE RELATIVE EFFICACY OF FAVEZELIMAB WHEN USED IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH PD-1–REFRACTORY CLASSICAL HODGKIN LYMPHOMA |
| title_full | P1067: ESTIMATING THE RELATIVE EFFICACY OF FAVEZELIMAB WHEN USED IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH PD-1–REFRACTORY CLASSICAL HODGKIN LYMPHOMA |
| title_fullStr | P1067: ESTIMATING THE RELATIVE EFFICACY OF FAVEZELIMAB WHEN USED IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH PD-1–REFRACTORY CLASSICAL HODGKIN LYMPHOMA |
| title_full_unstemmed | P1067: ESTIMATING THE RELATIVE EFFICACY OF FAVEZELIMAB WHEN USED IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH PD-1–REFRACTORY CLASSICAL HODGKIN LYMPHOMA |
| title_short | P1067: ESTIMATING THE RELATIVE EFFICACY OF FAVEZELIMAB WHEN USED IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH PD-1–REFRACTORY CLASSICAL HODGKIN LYMPHOMA |
| title_sort | p1067: estimating the relative efficacy of favezelimab when used in combination with pembrolizumab in patients with pd-1–refractory classical hodgkin lymphoma |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431435/ http://dx.doi.org/10.1097/01.HS9.0000971164.88567.72 |
| work_keys_str_mv | AT armandphilippe p1067estimatingtherelativeefficacyoffavezelimabwhenusedincombinationwithpembrolizumabinpatientswithpd1refractoryclassicalhodgkinlymphoma AT luigizinzanipier p1067estimatingtherelativeefficacyoffavezelimabwhenusedincombinationwithpembrolizumabinpatientswithpd1refractoryclassicalhodgkinlymphoma AT timmermanjohn p1067estimatingtherelativeefficacyoffavezelimabwhenusedincombinationwithpembrolizumabinpatientswithpd1refractoryclassicalhodgkinlymphoma AT johnsonnathalie p1067estimatingtherelativeefficacyoffavezelimabwhenusedincombinationwithpembrolizumabinpatientswithpd1refractoryclassicalhodgkinlymphoma AT laviedavid p1067estimatingtherelativeefficacyoffavezelimabwhenusedincombinationwithpembrolizumabinpatientswithpd1refractoryclassicalhodgkinlymphoma AT thiagarajankannan p1067estimatingtherelativeefficacyoffavezelimabwhenusedincombinationwithpembrolizumabinpatientswithpd1refractoryclassicalhodgkinlymphoma AT toppbrian p1067estimatingtherelativeefficacyoffavezelimabwhenusedincombinationwithpembrolizumabinpatientswithpd1refractoryclassicalhodgkinlymphoma AT pillaipallavi p1067estimatingtherelativeefficacyoffavezelimabwhenusedincombinationwithpembrolizumabinpatientswithpd1refractoryclassicalhodgkinlymphoma AT herreraalexf p1067estimatingtherelativeefficacyoffavezelimabwhenusedincombinationwithpembrolizumabinpatientswithpd1refractoryclassicalhodgkinlymphoma |